Takeda Pharmaceutical Co. $TAK Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,088 shares of the company’s stock after acquiring an additional 715 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Takeda Pharmaceutical were worth $341,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 21.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock worth $87,000 after buying an additional 1,003 shares in the last quarter. GAMMA Investing LLC grew its stake in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Takeda Pharmaceutical in the first quarter valued at about $125,000. Hexagon Capital Partners LLC lifted its position in shares of Takeda Pharmaceutical by 52.9% in the first quarter. Hexagon Capital Partners LLC now owns 8,698 shares of the company’s stock worth $129,000 after buying an additional 3,008 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth about $156,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

TAK stock opened at $14.03 on Friday. The business’s 50-day moving average price is $14.75 and its two-hundred day moving average price is $14.74. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The firm has a market cap of $44.63 billion, a PE ratio of 46.75 and a beta of 0.21. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TAK shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.